Skip to content
ClinCalc Pro
Menu
Bismuth salt (anti-diarrhoeal / antacid)

Bismuth subsalicylate

Brand names: Pepto-Bismol

Bismuth subsalicylate is used for the symptomatic relief of dyspepsia, mild diarrhoea and nausea, and forms part of some Helicobacter pylori eradication regimens.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It exerts a local antisecretory, anti-inflammatory and antibacterial action on the gastrointestinal mucosa, with the salicylate moiety contributing antisecretory effects within the gut.

Prescribing in practice

  • Because it releases salicylate, it should be avoided in children and adolescents with viral illness owing to the risk of Reye's syndrome, and used with caution in patients with salicylate hypersensitivity or those taking other salicylates or anticoagulants.
  • It can cause harmless but striking blackening of the tongue and stools, which should not be mistaken for melaena.
  • Avoid prolonged high-dose use because of the potential for bismuth accumulation and salicylate toxicity.

Monitoring

No routine monitoring is required for short-term use; review if symptoms persist or with prolonged or high-dose administration.

Counselling the patient

  • Your stools and tongue may turn black, which is harmless and reversible.
  • Do not give salicylate-containing products to children or teenagers with a feverish illness.
  • Tell your prescriber if you take blood-thinning medicines or other aspirin-like drugs.

Evidence & guidelines

Bismuth subsalicylate has long-established use for gastrointestinal symptom relief and within combination Helicobacter pylori eradication regimens.

Reference: NaTHNaC; NICE CKS; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.